Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"

According to Zhitong Finance APP, Danish-based global pharmaceutical giant Novo Nordisk plans to launch more than five blockbuster drugs in the coming years as the company strives to maintain its competitiveness in the increasingly crowded obesity treatment market. At its Capital Markets Day, the Danish pharma company committed to introducing more than five blockbuster products in the coming years and achieving over $23 billion in additional sales. However, its share price plunged as much as 7.7% in early European trading. Novo Nordisk’s US ADRs (NVO.US) also weakened significantly in the US pre-market on Monday, at one point dropping more than 7%.

Novo Nordisk’s latest $23 billion target for incremental sales fell short of market expectations. "Investors are selling the stock because they didn’t see specific new catalysts to lift Novo Nordisk’s share price," Nordnet investment economist Per Hansen wrote in a report.

The global market for weight-loss drugs still harbors massive unmet demand. The long-term growth fundamentals stem from increased treatment penetration and expanded indications. The World Health Organization points out that there are over a billion people globally suffering from obesity. Even with rapid capacity expansion, by 2030 GLP-1 therapies are still expected to cover less than 10% of potentially eligible patients.

Novo Nordisk Reveals Future Blockbuster Drug Launch Plans, but Investors Are Left Disappointed

After losing its absolute lead and being continuously surpassed by Eli Lilly in the booming obesity treatment market, investors originally expected CEO Lars Fruergaard Jørgensen to deliver a more concrete turnaround plan. However, the Danish pharma giant appears to have let them down.

Although Novo Nordisk was among the first to introduce a new generation of potent drugs making obesity easier to treat, it still lags behind Eli Lilly.

"We need to work harder, and we will," Jørgensen said at an event in London. He stated that Novo Nordisk would explore acquisition opportunities while also expanding its own R&D pipeline.

However, this presentation did not provide details on what would exactly drive growth. Some of the anticipated growth is expected to come from the next-generation product CagriSema, whose clinical trial results have disappointed investors multiple times, including in a head-to-head study where it failed to reach the efficacy level of Eli Lilly’s blockbuster weight-loss drug Zepbound.

Other potential growth drivers are compounds still in earlier-stage research and development, and thus carry a higher risk of failure.

As Jørgensen pushes Novo Nordisk to adopt a more aggressive strategy, he has reduced the workforce and management layers. Last week, the company dropped “Nordisk” from its everyday branding to raise its profile.

A series of disappointing clinical trial results has led some investors to question whether the company can successfully achieve growth as key blockbuster drugs face increasing competition from generics. Ozempic and Wegovy are expected to face patent expirations in Europe and the US in the early 2030s.

Novo Nordisk previously stated that its overall profit and revenue this year could fall by as much as 6%.

The $100 Billion Weight-Loss Drug Market Enters the Endgame: Efficacy, Capacity, and Payer Ability

The mainstream forecast for the pure weight-loss drug market by around 2030 ranges from approximately $95 billion to $105 billion. If diabetes, cardiovascular, and other metabolic indications are included, the broad market ceiling could approach $200 billion.

Goldman Sachs’ latest forecast predicts the global anti-obesity drug market to reach about $95 billion by 2030. Morgan Stanley’s base case is $105 billion, with its optimistic scenario at $144 billion. Using the 2023 sales figure of about $6 billion as the starting point, the base case implies a compound annual growth rate of around 50.5% from 2023 to 2030. JPMorgan, with a wider inclusion standard, expects the global incretin market—including diabetes and obesity indications—to reach $200 billion by 2030.

Novo Nordisk’s newly proposed blueprint for upcoming drugs illustrates its intention to capture the next growth cycle through product iteration. This target corresponds to the sales contributions of pipeline products. The share price fell as much as 7.7% in early trading, reflecting investor calls for more concrete growth targets and market focus on when new drugs will reach the market, how they will differentiate, and how revenue will continue to grow in the coming years. Facing Eli Lilly’s competition and impending patent cliffs for core products in the early 2030s, clear clinical, launch, and commercialization timelines will directly influence how the market values this long-term blueprint.

For weight-loss drug leaders Novo Nordisk and Eli Lilly, the long-term blueprint aims to convert weight reduction into lasting health benefits, creating a more comprehensive metabolic disease treatment system. R&D endpoints will further cover cardiovascular events, kidney function deterioration, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, as well as joint pain and mobility improvements.

Certain expanded weight-loss drug products already have regulatory foundations: Novo Nordisk’s Wegovy is approved to reduce the risk of major adverse cardiovascular events in eligible obese or overweight patients with cardiovascular disease, and Zepbound is also approved to treat moderate to severe obstructive sleep apnea in obese adults. Meanwhile, oral formulations, low-frequency long-acting dosing, improved gastrointestinal tolerability, and more sustainable weight maintenance solutions will remain focal points of competition. Investment value will increasingly concentrate on products that demonstrate fat reduction, long-term treatment sustainability, and added benefits for complications, as this evidence helps expand the eligible population and strengthen payer support.

The next generation of weight-loss drugs will first focus on more significant weight reduction, higher-quality improvements in body composition, and more expansive efficacy. Multi-target designs seek to synergistically regulate appetite, satiety, glycemic control, and energy metabolism for deeper therapeutic effects. For example, the pipeline drug retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously; Eli Lilly’s TRIUMPH-1 Phase III results showed the 12 mg group achieved an average weight loss of 28.3% at 80 weeks under a maintained-treatment analysis, and 25.0% accounting for treatment discontinuation and other factors. Novo Nordisk’s zenagamtide, originally known as amycretin, is a single-molecule GLP-1/amylin dual receptor agonist exploring complementary satiety signaling. Another research direction is increasing the proportion of fat reduction while preserving as much lean mass as possible and demonstrating benefits for muscle strength and physical function; in the BELIEVE Phase II study, the combination of bimagrumab and semaglutide provided clinical evidence for this optimization of body composition.